Breakthrough Therapy Status For Ianalumab Could Be A Game Changer For Novartis (SWX:NOVN) [Yahoo! Finance]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Yahoo! Finance
monoclonal antibody with a dual B-cell and BAFF-R–blocking mechanism, supported by positive replicate Phase III data in a condition with no approved targeted treatments. Together with Novartis's new AI- and data-enabled cardiovascular disease prevention partnership in Brunei and progress on a licensed Lipoprotein(a) therapy, these developments underscore the company's push to pair advanced biologics with data-driven care models across immunology and cardiovascular medicine. Against this backdrop, we'll explore how the Breakthrough Therapy designation for ianalumab shapes Novartis's broader investment narrative in immunology. These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs . Discover why before your portfolio feels the trade war pinch. For me, the core Novartis thesis hinges on whether you believe its mix of high-quality earnings, disciplined capital returns and a growing pipeline can justify the premium the market i
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- NFL Greats and Novartis Tackle Prostate Cancer Myths at Super Bowl LX: "Relax, It's a Blood Test"PR Newswire
- Eaton Vance Worldwide Health Sciences Fund Reduces Stake in Novo Nordisk AS by 49.25% [Yahoo! Finance]Yahoo! Finance
- Jim Cramer is Optimistic About Novartis' (NVS) Cancer Drug [Yahoo! Finance]Yahoo! Finance
- Why I Am Buying the Schwab International Equity ETF (SCHF) and Never Looking Back [Yahoo! Finance]Yahoo! Finance
- Novartis (NYSE:NVS) is now covered by analysts at Citigroup Inc.. They set a "buy" rating on the stock.MarketBeat
NVS
Earnings
- 10/28/25 - Miss
NVS
Sec Filings
- 1/16/26 - Form S-8
- 1/16/26 - Form S-8
- 1/16/26 - Form S-8
- NVS's page on the SEC website